Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer

Sponsor
Yang Zhijun
Study ID
NCT03298074
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib, 500mg,po qd for continuous administration
  • Etoposide — DRUG
    Etoposide,100mg, PO.QD，D1-D10, Q3W

Study Details

It is a prospective multi-center trial, platinum-resistant ovarian cancer patients will be randomized in two groups, one group will be treated with Apatinib plus Etoposide, the other will be treated with Etoposide alone. It is aimed to see the efficacy and safety of Apatinib plus Etoposide for the platinum-resistant ovarian cancer patients

Key Dates

Start date
Oct 31, 2017
Status verified
Sep 2017
Primary completion
Oct 31, 2018
Completion
Apr 30, 2019

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib plus Etoposide
    Apatinib,500mg,PO.QD, continuous administration Etoposide,100mg, PO.QD，D1-D10, Q3W
  • Active Comparator: Etoposide
    Etoposide,100mg, PO.QD，D1-D10, Q3W

Primary Outcome Measure

Disease Control Rate [ Time Frame: through study completion, an average of 1.5 years ]

Central Contacts

Related Studies